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Vaccinia Tian Tan (VTT) was used as a vaccine against smallpox in China for millions of people before 1980, yet the biological
characteristics of the virus remain unclear. We have characterized VTT with respect to its host cell range, growth properties in vitro, and
virulence in vivo. We found that 11 of the 12 mammalian cell lines studied are permissive to VTT infection whereas one, CHO-K1, is non-
permissive. Using electron microscopy and sequence analysis, we found that the restriction of VTT replication in CHO-K1 is at a step before
viral maturation probably due to the loss of the V025 gene. Moreover, VTT is significantly less virulent than vaccinia WR but remains
neurovirulent in mice and causes significant body weight loss after intranasal inoculation. Our data demonstrate the need for further
attenuation of VTT to serve either as a safer smallpox vaccine or as a live vaccine vector for other pathogens.
D 2005 Elsevier Inc. All rights reserved.
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Smallpox is a deadly human disease that is caused by the
infection of the variola virus, a member of the orthopoxvirus
genus (Moss, 1991). Because the mortality rate of smallpox
is over 50%, millions of lives were lost to this disease over
the last century before the introduction of an effective
vaccine. Vaccinia virus is another member of the orthopox-
virus genus (Moss, 1991). Since vaccinia virus has mutual
immunogenicity with variola virus and only causes mild
complications in humans, the use of the vaccinia virus as a
smallpox vaccine enabled aggressive immunization pro-
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1 These authors contribute equally to this work.to the declaration of complete variola eradication in the
world by 1979 (Breman and Arita, 1980; Fenner, 1982;
Mayr, 1999; Strassburg, 1982; or http://www.who.int/emc/
diseases/smallpox/Smallpoxeradication.html).
The history of smallpox in China can be traced back to
Han Dynasty (206–202 B.C.) (Ma, 1995). The smallpox
was not preventable until Chinese invented variolation in
North Song Dynasty (960–1127 A.D.), which was probably
the earliest practice of smallpox prevention (Ma, 1995). By
the time of Qing Dynasty (1644–1911 A.D.), variolation
was promoted in Kangxi reign to reduce the mortality in the
imperial family (Chang, 1996). Variolation was largely
supplanted by Edward Jenner’s cowpox vaccine discovered
in 1798, but it was not officially proscribed till 1950s
(Strassburg, 1982; Yutu et al., 1988). When the smallpox
vaccination program was interrupted, variolation was
renewed in some remote areas in China which caused
several outbreaks of smallpox in 1960s (Yutu et al., 1988).
During the smallpox eradication campaign in 1960–1970s,05) 242–251
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the vaccinia Tian Tan (VTT) strain (Jin et al., 1997a,
1997b). VTT exhibits good immunogenicity, moderate
reactogenicity, and relatively mild complications in humans.
Due to these natural properties, VTT was successfully used
for millions of Chinese to prevent smallpox infection
between 1920 and 1980, which subsequently led to the
variola eradication in China before 1980 (http://www.who.
int/emc/diseases/smallpox/Smallpoxeradication.html).
Despite such extensive human use, however, many of the
biological characteristics of the vaccine strain VTT remain
unknown.
Recently, vaccinia virus attracted more attention for its
re-use as a vaccine against variola virus, due to the rise in
bio-terrorism threats around the world (Mahalingam et al.,
2004; Weltzin et al., 2003). This is a significant security
concern because about 40% of people in the United States,
for example, are younger than 30 years old and are not
vaccinated. Moreover, vaccinia virus can also be engineered
to deliver foreign antigens to serve as a live vaccine vector
for other pathogens (Moss, 1996; Paoletti, 1996). As an
AIDS vaccine candidate, an attenuated modified vaccinia
Ankara (MVA) expressing HIV-1 components has entered
clinical trials (McMichael and Hanke, 2002). Considering
the potential future use of VTT in humans, we attempt to
determine the biological properties of the virus.
Based on sequence analysis, VTT displays genetic
features distinct from other vaccinia viruses, including the
Western Reserve (WR) strain (Hou et al., 1985; Jin et al.,
1997a; Tsao et al., 1986). These data infer the plausibly
distinct biological properties of VTT. In recent years, VTT
was explored as a live vector for other pathogens such as
rabies virus and hepatitis B virus (Guo et al., 2001; Zhu et
al., 1996). These studies, however, are still preliminary. Up
to now, few data are available with respect to the baseline
biological properties of VTT, which is essential for assess-
ments of the safety and immunogenicity of a vacciniaTable 1
Replication and spread of VTT in various cell types infected with 0.05 moi of th
Cell line ATCC code Species Organ
HeLa CCL-2 Human Cervix
MRC-5 CCL-171 Human Lung
293T CRL-11268 Human Kidney
WISH CCL-25 Human Amnion
Vero CCL-81 African green Monkey Kidney
COS-7 CRL-1651 African green Monkey Kidney
PK(15) CCL-33 Pig Kidney
MDCK CCL-34 Dog Kidney
RK13 CCL-37 Rabbit Kidney
C6 CCL-107 Rat Glial tum
CHO-K1 CCL-61 Chinese Hamster Ovary
BHK-21 CCL-10 Syrian Hamster Kidney
CEF Primary Chicken embryo Assorted
a Virus spread as visualized by immunostaining after 48 h. , no stained cells; +
stained cells (Carroll and Moss, 1997).
b Virus replication (fold increase in virus titer) determined by dividing the virus y
into permissive (P, N25-fold increase) and nonpermissive (NP, b1-fold increase) cexpression vector (Meyer et al., 1991; Moss, 1996; Paoletti,
1996). In this study, the smallpox vaccine VTT is studied in
relation to its host range, growth properties, morphogenesis,
and virulence. Our findings will serve as a baseline for
further modification of the virus, as either a safer smallpox
vaccine or a live vaccine vector for other pathogens.Results
Host range of VTT strain
Twelve mammalian cell lines of various host origins and
primary chicken embryo fibroblasts (CEF) were tested in
this study (Table 1). Using immunochemical staining, we
found that each cell type tested can be infected by VTT.
This is indicated by the expression of specific viral antigen
stained with polyclonal anti-vaccinia serum in infected cells
(Fig. 1). Except for CHO-K1, all cell types show positive
foci, which consist of a cluster of stained cells. However,
the number of positive cells and the extent of cytopathic
effects is different in each cell type. We scored the observed
foci by counting the positive cells post-infection (pi)
according to a method previously described (Table 1)
(Carroll and Moss, 1997). CHO-K1 is deemed non-
permissive since only individually positive cells were
observed 24 h pi and the number of infected cells tended
to decrease 48 h pi (Fig. 1). In contrast, clear cytolytic
effects and large plaques were found 48 h pi in eight
permissive cell types including HeLa, MRC-5, Vero, COS-
7, MDCK, RK13, C6, BHK-21, and primary CEF cells.
Importantly, the growing size of each positive foci or
plaque overtime in these cell types also suggests that the
cell–cell contact is essential for viral transmission or spread.
In particular, COS-7 cells show the most rapid cell killing
(Fig. 1B). Large plaques were frequently seen in COS-7 by
24 h pi. Vero cells seem to give the highest yield ofe virus
Morphology Virus spreada Virus replicationb
Epithelial +++ 63.6 P
Fibroblast +++ 187.5 P
Epithelial +++ 69.1 P
Epithelial +++ 33.8 P
Epithelial +++ 562.5 P
Fibroblast +++ 247.9 P
Epithelial ++ 100.8 P
Epithelial +++ 145 P
Epithelial +++ 131.3 P
or Fibroblast +++ 156.7 P
Epithelial /+ 0.12 NP
Fibroblast +++ 62.5 P
Fibroblast +++ 128.1 P
, foci of 1–4 stained cells; ++, foci of 5–25 stained cells; +++, foci of N25
ield at 72 h by the practical input titer. Cell lines were therefore categorized
ells (Carroll and Moss, 1997).
Fig. 1. Infection and cell-to-cell spread of VTT in various cell types including one primary chicken fibroblast (1A) and 12 cell lines (1B). The cells were
infected with 100 PFU of VTT per well in a 24-well-plate, and then fixed and immunostained with anti-vaccinia antibody at 24 and 48 h pi. All these photos
were taken at the 100 magnification.
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reaching 562.5-fold by 72 h pi (Table 1). Such titer is more
than doubled than that of CEF (128.2-fold) which was used
for VTT manufacture before 1980 (Table 1). The data
suggest the potential use of Vero cell for manufacturing
VTT virus in the future. For 293T and WISH cells, typical
cytolytic plaques usually began to become predominant
after 72 h pi, suggesting relatively slower cell killing in
these cell types. In PK(15) cells, no severe cytolytic effects
were found although small clusters of infected cells were
identified, which may suggest a different cytopathic
mechanism in this cell type. Moreover, the much fewer
positive cells found in each foci at 48 h pi also indicated
that the viral spread via cell-to-cell contact is less efficient
in PK(15) cells.
Replication of VTT under low multiplicity of infection
To further understand the replication kinetics of vaccinia
VTT in various cell types tested, we infected the cells at a
low multiplicity of infection (moi). Using a 0.05 moi, we
determined the growth of viral replication for multiple
rounds (Carroll and Moss, 1997). We found that VTT
replicated with similar kinetics in four human cell lines
including HeLa, MRC-5, 293T, and WISH (Fig. 2A). Since
these cells were derived from human cervix epithelial, lungFig. 2. Replication of VTT in cell types tested. Cells were infected with 0.05 moi (
viral absorption, and 24, 48, and 72 h pi. Moreover, cells were infected with 5 moi
viral absorption, and 12 and 24 h pi. In these experiments, both culture mediumfibroblast, kidney epithelial, and amnion epithelial, respec-
tively, VTT can replicate efficiently in cell types with
diverse tissue origin. In these cells, the viral replication
quickly reached peak level around 24–48 h pi (Fig. 2A).
Interestingly, the cytolytic effects seem to occur quickly and
more severe in MRC-5 cells, a fibroblast lineage (Fig. 1B).
This finding is consistent with the data generated in nine
non-human cell types including Vero, COS-7, CHO-K1,
BHK-21, MDCK, RK13, PK(15), C6, and CEF. VTT tends
to replicate better and cause more severe cytopathic effects
in cells of fibroblast lineage such as COS-7 and C6
regardless of the host origin (Fig. 1B and Table 1). The
similar growth kinetics of VTT found in several cell types
makes it possible to use one of them to replace CEF cells for
vaccine production (Fig. 2B). Consistent with host range
study, TT does not seem to replicate in CHO-K1 cells with
the 0.05 moi for infection.
Replication of vaccinia VTT under high moi
A high moi usually results in synchronized infection in
viral target cells. Since a synchronized infection predom-
inantly reflects intracellular virus replication, we attempt to
predict the number of infectious viral particles produced
daily in each cell. In this experiment, the cells were infected
with a high moi of 5. After infection, the cells wereA and B). Viral replication was determined by measuring the viral titer after
(C and D). Viral replication was determined by measuring the viral titer after
and cells were harvested for testing.
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h. Under these conditions, we found that significant yields
of VTT were obtained from the four human cell lines HeLa,
MRC-5, 293T, and WISH (Fig. 2C) as well as from many
non-human cells including Vero, BHK-21, MDCK, RK13,
COS-7, PK(15), C6, and CEF (Fig. 2D). As expected, we
did not see viral production in the non-permissive CHO-K1
cells (Fig. 2D). The yield of viral particles in each cell type
has been summarized in Table 2. Considering the data of
day 0 largely reflect the quantity of input virus, we have
subtracted the values of day 0 for the calculation of viral
yield for later time points. Generally, most cell types
produced more than one plaque forming unit (PFU) of
infectious VTT per cell except for CHO-K1 at 24 h pi (Table
2). Vero cells, on average, produced the highest amount of
virus with an approximated ratio of about 29 virions per cell
in 24 h pi (Table 2). Since Vero is currently used to produce
human rabies and Japanese B encephalitis vaccines in China
(Dong et al., 2002; Yan et al., 2002), our findings have
demonstrated the potential use of this cell line to produce
VTT-based smallpox vaccine if needed. Of interest, all cell
types tested, including the non-permissive CHO-K1 cell,
exhibited severe cytopathic effects 24 h after VTT infection
(Table 2). This finding indicated that VTT-infected cells
may undergo cell death rapidly. Moreover, this finding also
suggested that the blockade of viral replication in CHO-K1
cells may not be at the entry step because the observed cell
death might be a result of viral infection.
Virus morphogenesis in permissive and non-permissive cells
To understand the blockade of viral replication in CHO-
K1 cells, vaccinia VTT-infected cells were further subjected
to electron microscope (EM) analysis. By analyzing the
morphology of newly produced viral particles, we expectedTable 2
Cytopathic effects and yield of VTT in various cell types infected with 5
moi of the virus
Cell line CPEa PFU/cell, 24 h
12 h 24 h
HeLa ++++ ++++ 3.75
MRC-5 ++++ ++++ 17.18
293T ++++ ++++ 9.5
WISH ++++ ++++ 5.23
Vero ++++ ++++ 29.5
COS-7 ++++ ++++ 14.45
PK(15) ++ +++/++++ 12.54
MDCK ++++ ++++ 1.13
RK13 ++++ ++++ 5.31
C6 ++++ ++++ 7.1
CHO-K1 ++++ ++++ 0.11
BHK-21 ++ +++ 10.14
CEF ++ +++ 5.36
a CPE was categorized by the following criteria: no difference from
control, ; b25% CPE, +; 25–50% CPE, ++; N50–75% CPE, +++; N75–
100% CPE, or high level cell detachment, ++++ (Carroll and Moss, 1997).to understand the life cycle of VTT in CHO-K1 cells. For
this reason, CHO-K1 and some permissive cells were
analyzed by EM 16 h pi. As shown in Fig. 3A, no
intracellular mature viruses (IMV) were found in infected
CHO-K1 cells although some immature virions were
frequently found in the cytoplasm of the infected cells. As
controls, the majority of the VTT particles showed the
characteristic brick-shape of IMV in the cytoplasm of
permissive cells including RK13, Vero, and CEF (Figs.
3B–D). Furthermore, viral particles at different stages of
viral maturation, like spherical immature virions, were
found in permissive cells as well (Figs. 3B–D). Therefore,
together with the finding of VTT-specific protein expression
in individual CHO-K1 cells (Fig. 1B), our data indicated
that the aborted viral replication in this cell line is likely due
to a blockade at the stage of viral assembly before
maturation. Considering that cowpox V025 gene determines
the virus growth in CHO cells (Ramsey-Ewing and Moss,
1995, 1998; Spehner et al., 1988), we have amplified the
gene homolog from our VTT. We found that our sequence is
99.9% identical to the V025 gene sequence of VTT
deposited in the GenBank (accession number AF095689).
Moreover, we found that VTT sequences contain many
similar mutations or deletions to WR strain when these
sequences were compared with the cowpox sequence
(AF482758) (data not shown). In particular, VTT and WR
share a nucleotide deletion in the V025 gene which resulted
in a reading frame shift and introduced a premature stop
codon at amino acid position 72. Therefore, like the
situation in WR, the loss of the functional V025 gene
probably contributes to the replication failure of VTT in
CHO-K1 cells.
Virulence of vaccinia VTT strain in BALB/c mice
Despite of the extensive use of vaccinia VTT in humans
in the last century, the virulence of the virus has not been
carefully determined. Here, we characterized the virulence
of the VTT by inoculating the virus into BALB/c mice. The
viral inoculums were based on the tissue infectious dose
(PFU) as determined in Vero cells. We first determine the
lethal dose (LD50 and LD90) of VTT by inoculating seven
groups of mice via the intracranial route. Each of the seven
groups, six mice per group, received one of 5-fold diluted
VTT. We found that the LD50 and LD90 of VTT were 3.1 
103 PFU and 1.4  104 PFU, respectively. The LD50 of
VTT, therefore, is about 300-fold less virulent in compar-
ison to that of vaccinia WR strain published previously,
which is about 10 PFU (Buller et al., 1985; Kutinova et al.,
1995). For a direct comparison, we also tested the LD50 and
LD90 of WR using the same method. The infectious dose of
WR was determined in Vero cells in parallel with VTT.
Most mice died after received WR except for some mice in
the group received 1 PFU of WR. We were able to obtain
the LD90 of WR which is 2.4 PFU. This LD90 value
indicates that WR is over 5000-fold more virulent than VTT
Fig. 4. Replication kinetics of VTT in mouse brain. BALB/c mice (3–4
weeks old) were inoculated intracranially with 10 Al containing 1.1  104
PFU of VTT. Mice were sacrificed daily, the intracranial contents were
homogenized in PBS, and the titer of infectious virus was determined by a
plaque assay on Vero cell monolayers. Each point on the curve represents
the average value of two mouse brains. The error bar indicates the
experimental variation.
Fig. 3. Electron microscopy analysis of four cell types infected with VTT. These cell types include CHO-K1 (A), RK13 (B), Vero (C), and CEF (D). The
analysis was performed at 16 h pi. The individual letters indicate different observed structures including: i, typical immature virion; m, brick-shaped mature
virion; n, nucleoid. The black bars shown at the left corner of each photo represent the equivalent physical sizes: 1 AM in A and B and 0.5 AM in C and D.
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replication kinetics of VTT in mouse brain, we inoculated 3
LD50 of VTT into ten mice via the same intracranial route.
Two animals were sacrifice daily for the titration of viral
replication in their brains. As shown in Fig. 4, VTT strain
replicated in the mouse brain with a peak viral yield of
1.71  104 PFU per brain on day 3 pi. Virus titer tended to
decline on day 4 pi, yet the remaining animals died on day
5 pi. These data demonstrated that VTT is likely a
neurovirulent virus.
The virulence of VTT was also tested by measuring the
body weight change of infected mice after they were
intranasally injected with viruses (Fig. 5). In contrast to
mock mice which received PBS, the infected mice showed
clear dose-dependent weight loss starting from the third day
after viral inoculation. There is a clear positive correlation
between the dose of virus inoculation and body weight loss
of the animals. A similar experiment was done by using the
WR strain. We inoculated two groups of BALB/c mice with
103 and 104 PFU of WR, respectively, via the intranasal
route. We found that 104 PFU of WR caused over 25%
weight loss in BALB/c mice, which was very similar to the
Fig. 5. Comparison of the virulence of VTT (A) and WR (B) in mice by the assessment of body weight loss of infected animals. Groups of five BALB/c mice
were infected intranasally with indicated doses of VTT or PBS, and WR or PBS on day 0 (arrow). The overtime body weight loss is represented by the mean
values of each group of animals post-viral infection. The error bar indicates the experimental variation.
Q. Fang et al. / Virology 335 (2005) 242–251248mice that received 106 PFU of VTT. Similarly, 103 PFU of
WR resulted in comparable weight loss with 105 PFU of
VTT in mice. This dose-dependent pattern is comparable to
that of WR in mouse model published previously (Brandt
and Jacobs, 2001). These results demonstrated that WR is
about 100 more virulent than VTTwhen the virus was given
via the intranasal route. Taken together, our data suggested
that VTT is much less virulent than vaccinia WR strain
although it remains to be neurovirulent.Discussion
In this study, we have characterized the biological
properties of the smallpox vaccine VTT strain by testing
its host cell range, growth properties, and virulence. We
found that VTT has a broad host cell range as the virus
infected all 13 different cell types of divergent host origins.
Various cell types, however, displayed different permissi-
bility and efficiency in supporting VTT replication. More-
over, we found that VTT could productively replicate in the
mouse brain and caused animal death after intracranial
infection. VTT also caused loss of mouse body weight after
intranasal infection. These findings indicated that VTT is a
neurovirulent virus and that it will need further attenuation
for future human use. Our data also established baseline
biological profiles for future VTT studies.
VTT has a broad host cell range. The biological
characteristics of multiple vaccinia strains have been
previously characterized such as strains of parental Ankara,
WR, Copenhagen, Wyeth, and Lister (Carroll and Moss,
1997; Kutinova et al., 1995; Meyer et al., 1991; Tartaglia et
al., 1992). One common property shared by these viruses is
their broad host cell range. Before the present study, the host
range of VTT was unclear despite the fact that the virus was
given to millions of Chinese as a smallpox vaccine before
1980, which probably made VTT the most extensively used
human smallpox vaccine in the world. Since VTT vacci-nation was quite effective against smallpox, the side effects
related to the biological properties of VTT were probably
ignored and not reported. Here, we found that VTT has
broad cell tropism to enter all 13 cell types tested despite the
virus was passaged on calf skin or CEFs for many
generations during the production of smallpox vaccine
(The Committee for Biological Product Standardization in
China, 1979). Thus, like many vaccinia viruses, VTT
probably uses similar common receptor or mechanism to
enter the broad range of target cells.
Despite of the broad host cell range, the replication
kinetics of VTT varies among different cell types. VTT
productively replicates in 12 of 13 mammalian or avian cells
except in non-permissive CHO-K1 cells. The infected cells,
however, displayed different efficiency in supporting the
VTT replication. For example, Vero cell produced the
highest yield of VTT whereas CHO-K1 cells only had
abortive infection. The viral yield depends not only on the
capability of each cell type to produce the progeny virions
but also on the efficiency of viral spread among cells. The
reason that Vero cells made the highest yield of virions is
very likely due to the fact that each Vero cell could produce
more virions than other cell types and VTT could spread
among Vero cells quickly (Tables 1 and 2). Since Vero cells
are currently used for human rabies, hepatitis A, and
Poliovirus vaccines manufacture in China and other
countries (Dong et al., 2002; Sampath et al., 2005; Sheets,
2000; Sun et al., 2004), our data suggested that this cell type
may be used to replace CEF to produce smallpox vaccine
VTT for use against bio-terrorism. This replacement will
eliminate the use of special pathogen free eggs and hence
help minimize the chicken-derived pathogens and reduce
the vaccine production cost substantially (Sheets, 2000).
However, we should also be cautious on other issues related
to the use of Vero cells for vaccine production. For example,
the specific Vero cell line recommended by WHO should be
used to avoid the potential contamination with SV40 or
some unexpected cellular proteins which may cause auto-
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2000). Using EM analysis, we found that the abortive
infection of VTT in CHO-K1 cells is likely due to a
blockade at viral maturation stage. Since this finding is
consistent to the previous report on vaccinia Ankara and
WR, there might be a common mechanism shared by these
vaccinia strains with VTT (Carroll and Moss, 1997;
Ramsey-Ewing and Moss, 1995; Spehner et al., 2000).
There are several possible factors related to the abortive
viral replication in CHO-K1 cells. First, some host cell
proteins, which are essential for viral maturation, might be
missing in CHO-K1 cells. Second, due to the loss of V025
gene by our sequence analysis, the shutoff of some vaccinia
intermediate and late protein synthesis in CHO-K1 cells
might lead to the aborted viral maturation (Ramsey-Ewing
and Moss, 1995, 1998). Third, some viral genes D13L,
A14L and A17L might also play a role in the morpho-
genesis of vaccinia virus (Rodriguez et al., 1997; Smith et
al., 2002; Wolffe et al., 1996). The exact mechanism,
however, remains to be further studied for VTT.
VTT is a neurovirulent vaccinia stain. To make a
vaccinia-based human vaccine, the safety profile of the
virus is one of the most essential elements (Meyer et al.,
1991; Tartaglia et al., 1992). Based on previous reports, the
LD50 of other vaccinia strains, such as Copenhagen and
Wyeth, was about 104 PFU by intracranial route in mice
(Kutinova et al., 1995; Tartaglia et al., 1992). Similarly, we
found that the LD50 of VTT is 3.1  103 PFU. However, if
we compare with the neurovirulent WR strain which has a
LD90 of 2.4 PFU, VTT is about 5000-fold less virulent with
a LD90 of 1.4  104 PFU. Nevertheless, VTT was able to
replicate in mouse brain with growth kinetics somewhat
similar to that of vaccinia Wyeth (Lee et al., 1992).
Moreover, VTT infection resulted in over 25% body weight
loss in BALB/c mice after 106 PFU of VTTwas intranasally
inoculated. In comparison, only 104 PFU of WR (100-fold
less than VTT) was needed to cause similar body weight
loss in vivo. Taking together these findings, we conclude
that although weaker than WR strain VTT remains to be a
neurovirulent vaccinia strain. If VTT is produced as
vaccines for future human use, further attenuation of the
virus should be considered. This is a serious concern
because VTT may be lethal to humans especially to
immune-compromised patients who often fail to control
systemic vaccinia replication.
VTT may be engineered to become a safe live-attenuated
vaccine vector. Currently, several highly attenuated vaccinia
strains have been developed as live viral vectors to make
vaccines for other pathogens including human immunode-
ficiency virus (Moss, 1996). In this study, we have
established the biological profile of VTT which may serve
as a baseline for future modification of the virus. Previously
highly-attenuated modified vaccinia Ankara (MVA) strain
was successfully obtained by serial passages of its parental
virus in CEF cells (Mayr et al., 1975, 1978). Similar
strategies have also been used to attenuate VTT throughserial passages of the virus on chick embryos or on human
diploid cells (Yang et al., 1979; Zhao et al., 1981). Given no
biological characterization was reported on the passaged
VTT virus, we do not know to what extent those viruses
have been attenuated. After some host range and virulence
genes were identified from the genome of vaccinia virus, the
introduction of selected deletions in viral genome has
become another approach to attenuate vaccinia virus
(Mackett et al., 1985; Ramsey-Ewing and Moss, 1995;
Tartaglia et al., 1992). This approach became possible for
VTT after the entire genomic structure of the virus was
documented (Jin et al., 1997a). Some preliminary results
have indicated that removing thymidine kinase gene or C–K
genomic may reduce the virulence of VTT (Li et al., 1999;
Zhu et al., 1996). These works showed some promising
progress yet the detailed biological characteristics on the
attenuated virus remain unknown. Considering the extensive
and successful human use of VTT against smallpox in the
history, we believe that understanding the biological proper-
ties of VTT is one of the fundamental steps for under-
standing the basis of the virus and for developing a safe
human vaccine (Katz and Moss, 1997; Smith et al., 2002;
Spehner et al., 2000; Weltzin et al., 2003).Materials and methods
Cells and virus
Twelve cell lines (Table 1) were grown under conditions
suggested by the American Type Culture Collection (ATCC,
Rockville, MD). The primary chick embryo fibroblasts
(CEFs) were prepared from 10-day-old chicken embryos.
The first generation of passaged CEF cells was used for
virus infections. VTT 761 strain was obtained from the
Institute of Virology, the Chinese Academy of Preventive
Medicine. Vaccinia WR strain was obtained from ATCC
(ATCC VR-1354, Rockville, MD). VTT and WR were
propagated in Vero cells. Viral stocks purified through
centrifugation over 36% sucrose cushion were used for in
vitro experiments while those used for in vivo testing were
further purified through sucrose density gradient centrifu-
gation (Joklik, 1962). Viral titers of VTT and WR were
determined on Vero monolayers by plaque assay using
crystal violet staining.
Immunostaining of virus plaques
Polyclonal anti-TT serum was produced in rabbits. This
antibody was used to detect virus-infected plaques or foci.
Two rabbits were immunized intradermally with 107 PFU of
VTT. Four weeks after, these rabbits were boosted twice
with 107 PFU of the purified TT stocks at a 3-week interval.
The animal was bled 4 weeks after the final inoculation. The
titer of anti-TT antibody in serum was determined in Vero
cells by a plaque reduction neutralization assay.
Q. Fang et al. / Virology 335 (2005) 242–251250For the test of cell-to-cell spread, plaques or foci of VTT
were immunostained by the rabbit anti-VTT serum using a
method previously described (Carroll and Moss, 1997). The
target cells were grown in 350-mm culture dishes to 90–
100% confluence and then infected with TT stocks at a
multiplicity of infection (moi) of 0.01. After absorption for
90 min, cells were washed three times with culture medium
and then incubated at 37 8C for another 24 h or 48 h before
immunostaining. After the incubation, cells were fixed with
a cold 1:1 solution of methanol/acetone for 2 min and then
incubated for 1 h at room temperature with antiserum diluted
(1:80) with phosphate buffered saline (PBS) containing 2%
fetal bovine serum (FBS). Cells were washed and then
incubated for 1 h at room temperature with Protein A
conjugated to horseradish peroxidase (Zhongshan Biotech;
1: 1500 dilution). After wash, the color was developed by
incubation up to 30 min with substrate solution consisting of
10 Al of 30% H2O2 and 0.2 ml of an ethanol solution
saturated with dianishidine (Sigma) in 10 ml of PBS.
Virus replication in vitro
Cells were grown in Falcon 24-well culture dishes to form
monolayers. The number of cells was calculated before the
virus inoculation so as to determine the input amount of virus.
VTT was then applied onto the cell monolayers at an moi of
0.05 in 100 Al of medium containing 3% FBS. After 90-min
incubation at 37 8C, cells were washed three times with
medium containing 3% FBS and replenished with fresh
culture medium. After wash, cells and supernatant were
harvested at 0, 24, 48, and 72 h pi. For one step growth
curves, cells were infected with an moi of 5. The samples
were harvested at 0, 12, and 24 h pi. After freeze–thawing
thrice, the viral titers were determined in duplicates on Vero
cells.
Electron microscopic analysis
Confluent cell monolayers were infected with 5 moi of
VTT. The virus was allowed to adsorb for 90 min at 37 8C.
The cells were then washed with medium three times and
incubated at 37 8C for an additional 16 h. Cells were then
trypsinized off the culture plates and washed with PBS
twice through centrifugation at 1200 rpm for 10 min. Then
the cell pellets were fixed in 2.5% glutaraldehyde and
processed for transmission electron microscopy using a
routine technique described previously (Wolffe et al., 1996).
Virulence in BALB/c mice
Groups of six 3- to 4-week-old BALB/c mice (equal
gender) were inoculated intracranially with one of 5-fold
diluted VTT or WR virus in 10 Al of sterile PBS. The LD50
was determined by the number of mice that succumbed
between 1 and 14 days pi by calculating the 50% end point
using the Reed-Muench method (Reed and Muench, 1938).With respect to VTT replication in mouse brain, 3- to 4-week-
old mice were inoculated intracranially with 1.1  104 PFU
(3LD50 ) of purified virus in 10 Al of PBS. Two of tested mice
were sacrificed daily, and their brains were homogenized in
PBS before they were subjected to viral titration.
The virulence of VTT in mice was also studied by their
weight loss after viral inoculation using a method previously
described (Zhang et al., 2000). Groups of five 5-week-old
BALB/c mice were inoculated intranasally with 0, 104, 105,
and 106 PFU of VTT in 30 Al of PBS. For comparison, 5-
week-old BALB/c mice were inoculated with 103 or 104
PFU of WR under the same conditions, respectively. The
body weight change of each mouse was monitored daily
and the mean value was used in the graph of the weight
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